Home › Kanser sa Balat › Texas
Pag-aaral pangklinika para sa Kanser sa Balat sa Texas
6 pag-aaral para sa Kanser sa Balat ang naghahanap ng mga kalahok sa mga site sa Texas.
Mga Lungsod sa Texas
Opisyal na teksto ng pag-aaral (English)
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
- The University of Texas at Austin Dell Medical School Ascension Medical Group, Austin
- U.S. Dermatology Partners, Cedar Park
- Reveal Research Institute, Dallas
- at 4 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT06585410Safety and Efficacy of OBX-115 in Advanced Solid Tumors
- M.D. Anderson Cancer Center (Melanoma/NSCLC), Houston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 16, 2026 · NCT06060613Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- JPS Health Network, Forth Worth
- Baylor Scott and White Biorepository, Temple
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT07327489Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
- The University of Texas MD Anderson Cancer Center, Houston
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 17, 2026 · NCT06947928A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
- MD Anderson Cancer Center, Houston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 13, 2026 · NCT06362369SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Dallas
- Massive Bio SYNERGY-AI site, Houston
- Massive Bio SYNERGY-AI site, Temple
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.